Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colony-stimulating factors. Present status and future potential.

R M Fox1

  • 1Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia.

Pharmacoeconomics
|December 9, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biocompatible, high precision, wideband, improved Howland current source with lead-lag compensation.

IEEE transactions on biomedical circuits and systems·2013
Same author

Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization.

Bone marrow transplantation·2006
Same author

Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials.

Internal medicine journal·2006
Same author

Debate: should Australia move towards a centralized ethics committees system? The case for.

Internal medicine journal·2005
Same author

Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital.

Internal medicine journal·2004
Same author

Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma.

Internal medicine journal·2004

Granulocyte colony-stimulating factors (G-CSF and GM-CSF) enhance neutrophil recovery in cancer patients undergoing chemotherapy. These agents show promise for optimizing chemotherapy doses and supporting stem cell transplantation alternatives.

Area of Science:

  • Oncology
  • Hematology

Background:

  • Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are established treatments to improve neutrophil recovery.
  • Their use is beneficial in patients with malignancies undergoing chemotherapy, with or without bone marrow transplantation.
  • CSFs offer potential healthcare cost reductions and improved therapeutic outcomes.

Purpose of the Study:

  • To identify patient populations and nonhematological malignancies that best respond to CSF support.
  • To determine the optimal CSF (G-CSF or GM-CSF) for specific clinical settings.
  • To explore the role of CSFs in chemotherapy dose intensification and peripheral blood progenitor cell transplantation.

Main Methods:

  • Clinical trials are ongoing to evaluate patient and malignancy-specific responses to CSF therapy.

Related Experiment Videos

  • Research focuses on assessing the efficacy of G-CSF and GM-CSF in various oncological and hematological conditions.
  • Investigating the use of CSFs for peripheral blood progenitor cell mobilization.

    • Main Results:

    • CSFs have demonstrated success in enhancing neutrophil recovery in patients with various malignancies.
    • CSFs facilitate chemotherapy dose intensification, potentially improving survival rates and disease-free intervals.
    • CSFs enable the collection of peripheral blood progenitor cells as an alternative to bone marrow transplantation.

    Conclusions:

    • G-CSF and GM-CSF are valuable agents in managing patients with malignancies undergoing chemotherapy.
    • CSFs hold significant potential for optimizing cancer treatment strategies, including dose intensification and stem cell support.
    • Future applications of CSFs extend to treating hematological malignancies and AIDS, impacting a broad range of conditions.